We are live on ! Find out more

Sagimet Biosciences

SGMT

Market cap $683M

10.98 USD

+0.10

0.92%

At close Updated Sep 14, 2:47 PM EDT

1 day

0.92%

5 days

1.29%

1 month

4.08%

3 months

69.71%

6 months

113.62%

Year to date

83.31%

1 year

72.64%

5 years

-31.16%

10 years

-31.16%

About: Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Employees: 16

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.2%

Neutral 77.8%

Negative 0%

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026.

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet's Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company's Series A common stock be granted on August 17, 2026 to the newly hired employees.

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executives said during a Canaccord Genuity discussion.

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026

Sagimet Biosciences is a catalyst-driven biotech, with value anchored to the upcoming U.S. Phase 3 denifanstat acne trial. SGMT's recent $175M equity raise extends cash runway through 2028, de-risking near-term financing and supporting Phase 3 execution. The U.S. Phase 3 trial aims to replicate strong China data, targeting best-in-class oral efficacy and safety in moderate-to-severe acne.

Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here).

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution.

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in 1x1 investor meetings at the Leerink Partners Therapeutics Forum in Boston, MA on July 15, 2026.

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

See News Rankings

Price charts implemented using Lightweight Charts™